A method for purifying and renaturing recombinant human IL-3 inclusion bodies

Through a multi-step purification regeneration method, including buffer washing and nickel column elution, the purification and regeneration process of recombinant human IL-3 inclusion bodies is optimized, solving the problems of inactivity and inefficiency of proteins in the prokaryotic expression system. , significantly improves protein purity and activity rate.

CN118834283BActive Publication Date: 2024-12-03JIANGSU KEYGEN BIOTECH CORP LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411324970.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-12-03
Estimated Expiration
2044-09-23

AI Technical Summary

Technical Problem

Recombinant human IL-3 inclusion bodies often exist in an inactive form in the prokaryotic expression system and require complex and inefficient regeneration processes to restore activity, resulting in insufficient protein purity and activity rate.

Method used

Multi-step purification regeneration method is adopted, including washing of buffers D and E, denaturing of buffers F, equilibration of buffers G and H, elution of buffers I, and buffers A, B and J dialysis, optimize the process to improve protein purity and viability.

Benefits of technology

It significantly improves protein purity and rejuvenation after rejuvenation, and has higher efficiency and effect than conventional techniques.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118834283B_ABST
    Figure CN118834283B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for purifying and renaturing recombinant human IL-3 inclusion bodies in the field of protein purification technology, including: (1) collecting human IL-3 inclusion bodies expressed by Escherichia coli; (2) washing human IL-3 inclusion bodies with buffer D and buffer E; (3) dissolving human IL-3 inclusion body protein with buffer F to obtain inclusion body denaturing solution containing lysed protein; (4) balancing a nickel column with buffer G, loading the inclusion body denaturing solution, washing with buffer H, and eluting human IL-3 protein with buffer I; (5) dialyzing and renaturing the eluted human IL-3 protein with buffer A, buffer B and buffer J to obtain renatured recombinant human IL-3 protein. The method provided by the present invention greatly improves the purity of the obtained protein, and multi-step renaturation further improves the activity rate after renaturation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of protein purification, and in particular relates to a method for purifying and renaturing recombinant human IL-3 inclusion bodies. Background Art

[0002] Interleukin 3 (IL-3) is an important hematopoietic growth factor that plays a key role in promoting the proliferation, differentiation and activation of a variety of hematopoietic cells. Current studies have found that it exhibits multi-lineage activity in in vitro and in vivo experiments.

[0003] Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells via recombinant human granulocyte colony-stimulating factor (rhG-CSF).

[0004] Human interleukin 3 (hIL-3) is a multipotent hematopoietic cytokine produced by mitogen- and antigen-activated keratinocytes, T lymphocytes, mast cells, NK cells, monocytes, and endothelial cells. Hematopoietic progenitor cells proliferate and differentiate into mature erythrocytes, mast cells, megakaryocytes, and granulocytes with the help of hIL-3 protein. The potential use of hIL-3 protein has been extensively tested in various clinical applications such as bone marrow transplantation, hematological malignancies, cytopenias, aplastic anemia, and various types of cancer.

[0005] Although IL-3 has broad application prospects in clinical and research fields, its production faces challenges, especially when using prokaryotic expression systems. It often exists in the form of inactive inclusion bodies and requires a complex and inefficient renaturation process to restore activity. Summary of the invention

[0006] The purpose of the present invention is to overcome the deficiencies in the prior art and provide a method for purifying and renaturing recombinant human IL-3 inclusion bodies, so that the purity of the obtained protein is greatly improved, and multi-step renaturation further improves the activity rate after renaturation.

[0007] To achieve the above object, the present invention is implemented by adopting the following technical solutions:

[0008] In a first aspect, the present invention provides a method for purifying and renaturing recombinant human IL-3 inclusion bodies, comprising the following steps:

[0009] (1) Collecting human IL-3 inclusion bodies expressed in Escherichia coli;

[0010] (2) Washing human IL-3 inclusion bodies using buffer D and buffer E;

[0011] (3) Dissolving human IL-3 inclusion body protein with buffer F to obtain inclusion body denatured liquid containing cleaved protein;

[0012] (4) Use buffer G to equilibrate the nickel column, load the inclusion body denaturation solution, wash with buffer H, and elute the human IL-3 protein with buffer I;

[0013] (5) dialyzing the eluted human IL-3 protein using buffer A, buffer B, and buffer J to obtain a reconstituted recombinant human IL-3 protein;

[0014] Wherein, buffer D: 90~110mmol / L Tris, 0.9~1.1V / V %TritonX-114, 90~110mmol / LNaCl, and pH 7.8~8.2;

[0015] Buffer E: 90-110 mmol / L Tris, 45-55 mmol / L NaCl, and pH 7.8-8.2;

[0016] Buffer F: 45~55mmol / L Tris, 5.5~6.5mol / L guanidine hydrochloride, and pH 7.8~8.2;

[0017] Buffer G: 45~55mmol / L Tris, 5.5~6.5mol / L urea, and pH 7.8~8.2;

[0018] Buffer H: 45~55mmol / L Tris, 5.5~6.5mol / L urea, 18~22mmol / L imidazole, and pH 7.8~8.2;

[0019] Buffer I: 45~55mmol / L Tris, 5.5~6.5mol / L urea, 230~270mmol / L imidazole, and pH 7.8~8.2;

[0020] Buffer A: 0.3~0.7mol / L urea, 0.45~0.55mol / L arginine, 1.9~2.1mmol / L GSH, 0.35~0.45mmol / L GSSH, 130~170mmol / L NaCl, 45~55mmol / L Tris, and pH 7.8~8.2;

[0021] Buffer B: 0.3~0.7mol / L urea, 0.15~0.25mol / L arginine, 1.9~2.1mmol / L GSH, 0.35~0.45mmol / L GSSH, 130~170mmol / L NaCl, 45~55mmol / L Tris, and pH 7.8~8.2;

[0022] Buffer J uses PBS buffer: 132~142mmol / L NaCl, 2.5~2.9mmol / L KCl, 9~11mmol / LNa2HPO4, 1.7~1.9mmol / L KH2PO4, and pH is 7.2~7.6.

[0023] In some embodiments, step (1) collecting human IL-3 inclusion bodies expressed by E. coli comprises:

[0024] The cells after induced expression were collected by centrifugation, and the cells were washed twice with buffer C to collect inclusion bodies;

[0025] The washing of the bacterial cells using buffer C comprises: resuspending the collected bacterial cells using buffer C at a ratio of 15-30 mL:1 g, ultrasonically disrupting, and centrifuging;

[0026] Buffer C: 95~105mmol / L Tris-HCl, 1.9~2.1V / V% Triton 100, 9~11mmol / L EDTA, 45~55mmol / L NaCl, and pH 7.8~8.2.

[0027] In some embodiments, in step (1), ultrasonic disruption is performed using an ultrasonic disruptor with a power of 60%; and centrifugation is performed at 12000 rpm for 15 to 30 min.

[0028] In some embodiments, step (2) uses buffer D and buffer E to wash the human IL-3 inclusion bodies, comprising: washing the human IL-3 inclusion bodies twice with buffer D, and then washing the human IL-3 inclusion bodies twice with buffer E.

[0029] Further, the IL-3 inclusion bodies are washed with buffer D, including: resuspending the human IL-3 inclusion bodies with buffer D at a ratio of 15-30 mL:1 g, ultrasonically disrupting, centrifuging, and collecting the human IL-3 inclusion bodies.

[0030] Further, the human IL-3 inclusion bodies are washed with buffer E, including: resuspending the human IL-3 inclusion bodies with buffer E at a ratio of 15-30 mL:1 g, ultrasonically disrupting, centrifuging, and collecting the human IL-3 inclusion bodies.

[0031] In step (2), ultrasonic disruption is performed using an ultrasonic disruptor with a power of 60%; and centrifugation is performed at 12000 rpm for 15 to 30 min.

[0032] In some embodiments, step (3) dissolving human IL-3 inclusion body protein with buffer F comprises: resuspending the inclusion body obtained in step (2) with buffer F, denaturing at 2-6°C overnight, and centrifuging and filtering to obtain denatured inclusion body solution.

[0033] In some embodiments, step (4) specifically includes:

[0034] Equilibrate the nickel column with 3 to 10 column volumes of buffer G;

[0035] Load the inclusion body denaturation solution obtained in step (3);

[0036] Re-equilibrate the nickel column with 3 to 10 column volumes of buffer G;

[0037] Use 3 to 10 column volumes of buffer H to wash the impurities;

[0038] The eluted protein was collected using buffer I for elution.

[0039] Furthermore, the flow rate of the sample loading is 0.5-1 column volume / min.

[0040] During elution with buffer I, the linear flow rate of the nickel column should not exceed 0.5 column volumes / min.

[0041] In some embodiments, step (5) specifically includes:

[0042] The eluted human IL-3 protein was placed in a dialysis bag and dialyzed in buffer A at 2-6°C for 12-24 hours;

[0043] The dialyzed protein is then placed in a dialysis bag and placed in buffer B for 24 to 60 hours at 2 to 6°C.

[0044] The dialyzed protein was then placed in a dialysis bag and placed in buffer J for dialyzation at 2-6°C for 24-60 hours.

[0045] Compared with the prior art, the present invention has the following beneficial effects:

[0046] The multi-step washing and optimized renaturation process of inclusion bodies has advantages in renaturation efficiency compared with conventional inclusion body denaturation and renaturation technology, and the protein purity is greatly improved. Multi-step renaturation further improves the activity rate after renaturation. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 Schematic diagram of SDS-PAGE of each component in the inclusion body purification process in the embodiment of the present invention, wherein: M is a marker, lane 1 is the denaturing solution after multiple washes, lane 2 is the nickel column flow-through solution, lane 3 is the buffer H washing solution, and lane 4 is the buffer I eluent.

[0048] Figure 2 Schematic diagram of SDS-PAGE of the renatured protein in the embodiment of the present invention, lane 1 is the reduced sample after renaturation, and lane 2 is the non-reduced sample after renaturation.

[0049] Figure 3 Schematic diagram of the results of the cell proliferation experiment in the embodiment of the present invention. DETAILED DESCRIPTION

[0050] The present invention is further described below in conjunction with the examples. The following examples are only used to more clearly illustrate the technical solutions of the present invention, and are not intended to limit the scope of protection of the present invention.

[0051] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features in the embodiments may be combined with each other.

[0052] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0053] For the purpose of this specification and the appended claims, unless otherwise stated, all numbers expressing amounts, percentages or ratios and other numerical values ​​used in this specification and the appended claims are understood to be modified in all cases by the term "about". In addition, all ranges disclosed herein are inclusive and independently combinable.

[0054] In the present application: GSH means glutathione; GSSG means oxidized glutathione.

[0055] Example 1

[0056] (1) Collection of inclusion body protein of rhIL-3 induced by E. coli: Centrifuge the BL21 cells induced to express rhIL-3 protein at 8000 rpm / min for 20 min, and separate the supernatant and precipitate after centrifugation. Resuspend the precipitate in buffer C at a ratio of 15 mL / g and then break it with ultrasound (ultrasound for 3 s, stop for 6 s, 60% power, 5 min), and centrifuge at 4°C at high speed, 12000 rpm, for 30 min. Repeat the above operation to wash the inclusion body.

[0057] (2) Washing inclusion bodies: Separate the supernatant from the precipitate. Resuspend the precipitate in buffer D at a ratio of 20 mL / g and then use ultrasound to break it (ultrasound for 3 seconds, stop for 6 seconds, 60% power, 5 minutes), and centrifuge at 4°C, 12,000 rpm, 30 minutes. Repeat the above operation to wash the inclusion bodies. Separate the supernatant from the precipitate. Resuspend the precipitate in buffer E at a ratio of 20 mL / g and then use ultrasound to break it (ultrasound for 3 seconds, stop for 6 seconds, 60% power, 5 minutes), and centrifuge at 4°C, 12,000 rpm, 30 minutes.

[0058] (3) Separate the supernatant and the precipitate. Resuspend the precipitate in buffer F at a ratio of 20 mL / g overnight.

[0059] The next day, high-speed centrifugation was performed at 12,000 rpm for 30 min at 4°C, and the supernatant was filtered through a 0.45 μm membrane for purification.

[0060] (4) Inclusion body purification

[0061] Column connection: Choose a Nickel-column of appropriate size (load capacity not exceeding 40 mg / mL, roughly estimate the amount of filler based on 5 g bacteria and 1 mL filler) and connect it between the peristaltic pump and the UV absorption detector, making sure to exhaust the air.

[0062] Balance: flush the column with ddH2O for 5CV, and then balance the column with the prepared buffer G for 5 column volumes;

[0063] Sample loading: flow rate 0.5-1CV / min, collect the flow-through;

[0064] Re-equilibration: Use buffer G for another 5CV. It is not necessary to equilibrate the UV absorbance to the baseline.

[0065] Washing: Use buffer H to elute the impurities, start collecting the peak, and stop collecting when the UV absorbance value remains unchanged.

[0066] Elution: Use buffer I to elute human IL-3 protein, and start collecting the peak until the UV reading decreases and no longer changes, then stop collecting.

[0067] Collect each component, take 5 μL of E. coli loading group and flow-through group for SDS-PAGE identification, the results are as follows Figure 1 shown.

[0068] (5) Inclusion body renaturation

[0069] The protein obtained by the above method was dialyzed at a volume ratio of 1:100 and dialyzed into buffer A; placed in a 4°C refrigerator with stirring and dialyzed for 16 hours;

[0070] The dialyzed protein sample was then dialyzed to buffer B at a volume ratio of 1:100; placed in a 4°C refrigerator with stirring and dialyzed for 48 hours;

[0071] The above renatured sample was renatured into buffer J (PBS buffer, pH 7.4) at a volume ratio of 1:100, placed in a 4°C refrigerator with stirring, and dialyzed for 48 hours. The dialyzed protein was identified by SDS-PAGE, see Figure 2 .

[0072] Buffer A: 0.5 mol / L urea, 0.5 mol / / L arginine, 2 mmol / L GSH, 0.4 mmol / L GSSH, 150 mmol / L NaCl, 50 mmol / L Tris, and pH 8.0;

[0073] Buffer B: 0.5 mol / L urea, 0.2 mol / L arginine, 2 mmol / L GSH, 0.4 mmol / L GSSH, 150 mmol / L NaCl, 50 mmol / L Tris, and pH 8.0;

[0074] Buffer C: 100mmol / L Tris-HCl, 2.0V / V% Triton 100, 10mmol / L EDTA, 50mmol / L NaCl, and pH 8.0;

[0075] Buffer D: 100mmol / L Tris, 1 V / V% TritonX-114, 100mmol / L NaCl, and pH 8.0;

[0076] Buffer E: 100 mmol / L Tris, 50 mmol / L NaCl, and pH 8.0;

[0077] Buffer F: 50mmol / L Tris, 6mol / L guanidine hydrochloride, and pH 8.0;

[0078] Buffer G: 50mmol / L Tris, 6mol / L urea, and pH 8.0;

[0079] Buffer H: 50mmol / L Tris, 6mol / L urea, 20mmol / L imidazole, and pH 8.0;

[0080] Buffer I: 50 mmol / L Tris, 6 mol / L urea, 250 mmol / L imidazole, and pH 8.0.

[0081] Buffer J uses PBS buffer: 137mmol / LNaCl, 2.7mmol / LKCl, 10mmol / L Na2HPO4, 1.8mmol / L KH2PO4, and pH 7.4. In this embodiment, the preparation method of each liter of buffer J is as follows: weigh 8g NaCl, 0.2g KCl, 1.44g Na2HPO4, and 0.24g KH2PO4, dissolve them in 800mL deionized water and adjust the pH to 7.4, then add deionized water to 1000mL, and sterilize by high pressure for standby use.

[0082] Example 2

[0083] TF-1 cells were used for cell proliferation experiments. The renatured recombinant human IL-3 was compared with commercial recombinant human IL-3. Cell growth was observed for 48 hours. The activity was tested using a kit. Figure 3 It was shown that the activity of the renatured recombinant human IL-3 was higher than that of commercialized recombinant human IL-3.

[0084] Calculate the required cell volume and culture medium volume based on the counting results and plating requirements. 6 cells / well / 0.1mL cell volume, measure 1 sample (with standard), make 3-fold serial dilution, a total of 9 dilutions, 3 replicates for each dilution, with 1 blank control, that is, 3×10×2 wells for plating. Count TF-1 live cell density 0.6×10 6 cells / mL, viability 95.42%, 1 96-well plate:

[0085] Actual culture medium volume: 0.1 mL × 70 wells × 1 96-well plate = 7 mL;

[0086] Actual cell suspension volume: (0.02×10 6 cells×70 holes) / 0.6×10 6 cells / mL=2.3mL;

[0087] Take out 2.3mL of cell suspension into a sterile centrifuge tube and centrifuge at 1000rpm for 5min at room temperature. Pour off the complete medium, add 5~10mL of RPM I-1640 and gently resuspend to wash the cells, centrifuge at 1000rpm for 5min at room temperature again, and repeat the operation 3 times (remove the residual of the initial complete medium to prevent the GM-CSF component contained in it from affecting the experimental results).

[0088] After the above three cell washing operations are completed, use 7 mL of basal culture medium to resuspend the washed cells, mix them thoroughly in the sample loading tank, use a dispenser to evenly aspirate 0.1 mL of cell suspension for plating, and seal the surrounding wells with 0.2 mL / well PBS to reduce the loss of culture medium evaporation.

[0089] Cross-mix, observe under a microscope, and place in a 37°C, 5.0% CO2 incubator for later use.

[0090] The highest concentrations of commercial IL-3 protein and refolded recombinant human IL-3 protein were adjusted to 100 μg / mL. According to the highest final concentration required for the sampled protein, the sample volume was 100 μL / well, and then the gradient dilution was performed. The dilution data are shown in the following table.

[0091] Table 1

[0092]

[0093] Gently add the diluted sample into the planned experimental wells by suspending it in the air. Mix the liquid as much as possible when adding the sample, and keep the amount of sample added consistent;

[0094] Incubate at 37°C for 3 days, during which the growth status of the cells is observed under a microscope;

[0095] Take out the 96-well plate from the incubator and observe it under a microscope. Then put it on a 96-well plate shaker and shake it for about 30 seconds to shake the cells evenly. Turn off the light of the clean bench (the color reagent needs to be protected from light), add 40μL of color reagent to each well of the suspended cells (200μL system). Wrap the 96-well plate with tin foil and place it in an incubator at 37℃, 5.0V / V% CO2 for incubation.

[0096] Read the absorbance at 490nm for 3h, then select the four-parameter fitting curve in GraphPad to calculate the EC 50 , and the results were analyzed and registered. The results are shown in Table 1.

[0097] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the technical principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for purifying and renaturing recombinant human IL-3 inclusion bodies, characterized in that: The following steps are involved: (1) Collecting human IL-3 inclusion bodies expressed in Escherichia coli; (2) Washing human IL-3 inclusion bodies using buffer D and buffer E; (3) Dissolving human IL-3 inclusion body protein with buffer F to obtain inclusion body denatured liquid containing cleaved protein; (4) Use buffer G to equilibrate the nickel column, load the inclusion body denaturation solution, wash with buffer H, and elute the human IL-3 protein with buffer I; (5) dialyzing the eluted human IL-3 protein using buffer A, buffer B, and buffer J to obtain a reconstituted recombinant human IL-3 protein; Wherein, buffer D: 90~110mmol / L Tris, 0.9~1.1V / V %TritonX-114, 90~110mmol / L NaCl, and pH 7.8~8.2; Buffer E: 90-110 mmol / L Tris, 45-55 mmol / L NaCl, and pH 7.8-8.2; Buffer F: 45~55mmol / L Tris, 5.5~6.5mol / L guanidine hydrochloride, and pH 7.8~8.2; Buffer G: 45~55mmol / L Tris, 5.5~6.5mol / L urea, and pH 7.8~8.2; Buffer H: 45~55mmol / L Tris, 5.5~6.5mol / L urea, 18~22mmol / L imidazole, and pH 7.8~8.2; Buffer I: 45~55mmol / L Tris, 5.5~6.5mol / L urea, 230~270mmol / L imidazole, and pH 7.8~8.2; Buffer A: 0.3~0.7mol / L urea, 0.45~0.55mol / L arginine, 1.9~2.1mmol / L GSH, 0.35~0.45mmol / L GSSH, 130~170mmol / L NaCl, 45~55mmol / L Tris, and pH 7.8~8.2; Buffer B: 0.3~0.7mol / L urea, 0.15~0.25mol / L arginine, 1.9~2.1mmol / L GSH, 0.35~0.45mmol / L GSSH, 130~170mmol / L NaCl, 45~55mmol / L Tris, and pH 7.8~8.2; Buffer J uses PBS buffer: 132~142mmol / L NaCl, 2.5~2.9mmol / L KCl, 9~11mmol / LNa2HPO4, 1.7~1.9mmol / L KH2PO4, and pH is 7.2~7.

6.

2. The method according to claim 1, characterized in that Step (1) collecting human IL-3 inclusion bodies expressed by E. coli, comprising: The cells after induced expression were collected by centrifugation, and the cells were washed twice with buffer C to collect inclusion bodies; The washing of the bacterial cells using buffer C includes: resuspending the collected bacterial cells using buffer C at a ratio of 15-30 mL:1 g, ultrasonically disrupting, and centrifuging; Buffer C: 95~105mmol / L Tris-HCl, 1.9~2.1V / V% Triton 100, 9~11mmol / L EDTA, 45~55mmol / L NaCl, and pH 7.8~8.

2.

3. The method according to claim 2, characterized in that In step (1), ultrasonic disruption is performed using an ultrasonic disruptor with a power of 60%; and centrifugation is performed at 12000 rpm for 15 to 30 min.

4. The method according to claim 1, characterized in that: Step (2) washing the human IL-3 inclusion bodies with buffer D and buffer E, comprising: washing the human IL-3 inclusion bodies twice with buffer D, and then washing the human IL-3 inclusion bodies twice with buffer E.

5. The method according to claim 4, characterized in that The human IL-3 inclusion bodies are washed with buffer D, including: resuspending the human IL-3 inclusion bodies with buffer D at a ratio of 15-30 mL:1 g, ultrasonically disrupting, centrifuging, and collecting the human IL-3 inclusion bodies.

6. The method according to claim 4, characterized in that The human IL-3 inclusion bodies are washed with buffer E, including: resuspending the human IL-3 inclusion bodies with buffer E at a ratio of 15-30 mL:1 g, ultrasonically disrupting, centrifuging, and collecting the human IL-3 inclusion bodies.

7. The method according to claim 1, characterized in that Step (3) specifically comprises: resuspending the inclusion body obtained in step (2) using buffer F, denaturing at 2-6°C overnight, and centrifuging and filtering to obtain denatured inclusion body solution.

8. The method according to claim 1, characterized in that Step (4) specifically includes: Equilibrate the nickel column with 3 to 10 column volumes of buffer G; Load the inclusion body denaturation solution obtained in step (3); Re-equilibrate the nickel column with 3 to 10 column volumes of buffer G; Use 3 to 10 column volumes of buffer H to wash the impurities; Elution was performed using buffer I and the eluted protein was collected.

9. The method according to claim 1 or 8, characterized in that: The flow rate of sample loading was 0.5-1 column volume / min.

10. The method according to claim 1, characterized in that Step (5) specifically includes: The eluted human IL-3 protein was placed in a dialysis bag and dialyzed in buffer A at 2-6°C for 12-24 hours; Then, place the dialyzed protein in a dialysis bag and dialyze it in buffer B at 2-6°C for 24-60 hours. The dialyzed protein was then placed in a dialysis bag and placed in buffer J for dialyzation at 2-6°C for 24-60 hours.

Citation Information

Patent Citations

  • Application of anti-aFGF-scFv in preparing antineoplastic medicament and preparation method thereof

    CN101318018A

  • Method for expressing and purifying human recombinant interleukin-3

    CN102146413A